WallStreetZenWallStreetZen

NASDAQ: SUPN
Supernus Pharmaceuticals Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Supernus Pharmaceuticals earnings were $64.5M for the trailing 12 months ending Jun 30, 2025, with 1,200% growth year over year. The latest SUPN earnings report on Jun 30, 2025 announced Q2 2025 earnings of $22.5M, down 290.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, SUPN reported annual earnings of $73.9M, with 5,512.8% growth.

SUPN past earnings growth

How has SUPN's earnings growth performed historically?

Company
1,200%
Industry
27.12%
Market
29.26%
SUPN's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
SUPN's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
SUPN's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

SUPN earnings history

Current Revenue
$665.1M
Current Earnings
$64.5M
Current Profit Margin
9.7%
SUPN's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

SUPN Return on Equity

Current Company
6.2%
Current Industry
18%
Current Market
32.4%
SUPN's Return on Equity (6.2%)... subscribe to Premium to read more.
High Return on Equity Performance

SUPN undefined

Current Company
4.7%
Current Industry
7%
SUPN is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when SUPN announces earnings.

SUPN undefined

Current Company
7.5%
Current Industry
13.9%
SUPN's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

SUPN vs Pharmaceutical Stocks

TickerEBITDAEarningsY/Y EarningsEPS
SUPN$162.85M$64.50M-12.26%$1.17
ALVO$165.19M$63.36M-89.25%$0.24
HCM$47.79M$37.73M-66.67%$0.20
BHC$3.05B$98.00M+100.00%$0.26
AMRX$536.01M$3.38M-38.52%$0.01
View Top Pharmaceutical Stocks

Supernus Pharmaceuticals Earnings Reports & History FAQ

What were Supernus Pharmaceuticals's earnings last quarter?

On SUPN's earnings call on Invalid Date, Supernus Pharmaceuticals (NASDAQ: SUPN) reported Q2 2025 earnings per share (EPS) of $0.40, up 11.11% year over year. Total SUPN earnings for the quarter were $22.50 million. In the same quarter last year, Supernus Pharmaceuticals's earnings per share (EPS) was $0.36.

If you're new to stock investing, here's how to buy Supernus Pharmaceuticals stock.

Is Supernus Pharmaceuticals profitable or losing money?

As of the last Supernus Pharmaceuticals earnings report, Supernus Pharmaceuticals is currently profitable. Supernus Pharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2025 was $64.50 million, a 1,131.09% increase year over year.

What was SUPN's earnings growth in the past year?

As of Supernus Pharmaceuticals's earnings date in Invalid Date, Supernus Pharmaceuticals's earnings has grown 1,200% year over year. This is 1,172.88 percentage points higher than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 27.12%. SUPN earnings in the past year totalled $64.50 million.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.